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Background
Formononetin, which is used as neuroprotective medicine,
was reported to have benefits for Alzheimer’s disease
(AD). However, little is known on how Formononetin
exerts these beneficial effects. In this study, we investigated
the molecular mechanisms through which Formononetin
increased soluble-APPa (sAPPa) secretion and thus was
neuroprotective in human-APP Swedish mutation cell cul-
tures (N2a-APP cell).
Method and results
By using N2a-APP cell cultures combined with hypoxia
treatment, we confirmed that chronic treatment with
Formononetin could have neuroprotective effects, which
was followed by reduced and increased Caspase3 activity
and cell viability. Strikingly, our data revealed that the
Caspase3-blocking effect of Formononetin was largely
mediated by stimulation of a-secretase cleavage of APP,
resulting in increased secretion of its soluble form,
sAPPa. Moreover, the protective effect of Formononetin
was totally inhibited by TAPI-2, an a-secretase complex
inhibitor, suggesting the role of the sAPPa pathway in
the neuroprotective response to Formononetin. Further-
more, we also revealed that the stimulation effect of
Formononetin on a-secretase activity was mainly a
result of up-regulating ADAM10 expression at the tran-
scriptional level.
Conclusion
Altogether, our study provides novel insights into how
Formononetin mediated stimulation of the ADAM10-
sAPPa pathway and resulting neuronal protective effect.
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